Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not

被引:36
作者
Singh, M [1 ]
Chesko, J [1 ]
Kazzaz, J [1 ]
Ugozzoli, M [1 ]
Kan, E [1 ]
Srivastava, I [1 ]
O'Hagan, DT [1 ]
机构
[1] Chiron Corp, Chiron Vaccines, Emeryville, CA 94608 USA
关键词
CD4; gp120; HIV; microparticle; vaccine;
D O I
10.1007/s11095-004-7666-6
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate the delivery of a novel HIV-1 antigen (gp120dV2 SF162) by surface adsorption or encapsulation within polylactide-co-glycolide microparticles and to compare both the formulations for their ability to preserve functional activity as measured by binding to soluble CD4. Methods. Poly (lactide-co-glycolide) microparticles were synthesized by a water-in-oil-in-water (w/o/w) emulsification method in the presence of the anionic surfactant dioctylsulfosuccinate (DSS) or polyvinyl alcohol. The HIV envelope glyocoprotein was adsorbed and encapsulated in the PLG particles. Binding efficiency and burst release measured to determine adsorption characteristics. The ability to bind CD4 was assayed to measure the functional integrity of gp120dV2 following different formulation processes. Results. Protein (antigen) binding to PLG microparticles was influenced by both electrostatic interaction and other mechanisms such as hydrophobic attraction and structural accommodation of the polymer and biomolecule. The functional activity as measured by the ability of gp120dV2 to bind CD4 was maintained by adsorption onto anionic microparticles but drastically reduced by encapsulation. Conclusions. The antigen on the adsorbed PLG formulation maintained its binding ability to soluble CD4 in comparison to encapsulation, demonstrating the feasibility of using these novel anionic microparticles as a potential vaccine delivery system.
引用
收藏
页码:2148 / 2152
页数:5
相关论文
共 20 条
[1]   Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics [J].
Bittner, B ;
Morlock, M ;
Koll, H ;
Winter, G ;
Kissel, T .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1998, 45 (03) :295-305
[2]   THE IMPORTANCE OF SURFACE-CHARGE IN THE OPTIMIZATION OF ANTIGEN ADJUVANT INTERACTIONS [J].
CALLAHAN, PM ;
SHORTER, AL ;
HEM, SL .
PHARMACEUTICAL RESEARCH, 1991, 8 (07) :851-858
[3]  
CHANG MF, 1997, PDA J PHARM SCI TECH, V51, P1
[4]  
Cleland J L, 1995, Pharm Biotechnol, V6, P439
[5]  
CLELAND JL, 1994, AIDS RES HUM RETROV, V10, P21
[6]   Developing an AIDS vaccine: Need, uncertainty, hope [J].
Emini, EA ;
Koff, WC .
SCIENCE, 2004, 304 (5679) :1913-1914
[7]  
ESPARZA J, 2001, B WORLD HEALTH ORGAN, V79, P1093
[8]   HIV vaccines [J].
Frey, SE .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1999, 13 (01) :95-+
[9]   Prospects for an AIDS vaccine: three big questions, no easy answers [J].
Garber, DA ;
Silvestri, G ;
Feinberg, MB .
LANCET INFECTIOUS DISEASES, 2004, 4 (07) :397-413
[10]   STABILITY OF ATRIOPEPTIN-III IN POLY(D,L-LACTIDE-CO-GLYCOLIDE) MICROSPHERES [J].
JOHNSON, RE ;
LANASKI, LA ;
GUPTA, V ;
GRIFFIN, MJ ;
GAUD, HT ;
NEEDHAM, TE ;
ZIA, H .
JOURNAL OF CONTROLLED RELEASE, 1991, 17 (01) :61-67